ADVERTISEMENT

Business Strategies

Latigo Raises $150m To Drive Its First Pain Drug Toward Phase III

Vertex has the first-in-class NaV1.8 inhibitor for acute pain, Journavx, but Latigo plans to bring forward multiple best-in-class options for acute and chronic pain against NaV1.8 and other targets.

ChromaDex Changing Name To Niagen Bioscience While Shifting Focus To Rx NAD+

A week after announcing 2024 full-year and fourth-quarter results, the firm says its corporate name will be Niagen Bioscience Inc. starting 19 March. It stated in its latest results that during 2024 it launched Niagen Plus line of pharmaceutical-grade Niagen.

Finance Watch: Sutro Halves Workforce, Cuts Lead ADC And CEO Moves On

Restructuring Edition: Biopharma companies used fourth-quarter updates to reveal job and program cuts to conserve cash, including Sutro, Agenus, Coherus, Inozyme and Atea. Also, Vincerx’s reverse merger was terminated and Vaccinex, Oncternal, Syros plan to voluntarily delist.

Herbalife Spends To Add Personalized Supplements Through Nutrition App, Enter Ketone Market

Direct seller has deals to fully acquire and 51% ownership of Link BioSciences, which formulates personalized supplements. It also announced a deal to acquire Pruvit Ventures, ketone supplements direct seller.

Amplitude Acquisition Marks Global Medtech Entry With High Potential In India For Zydus

Zydus Lifesciences plans to expand global markets for patented products of French orthopedic tech company Amplitude Surgicals which it is acquiring from PE firm PAI Partners and others. Could the European business also serve as a buffer to upheaval in the US amid talks of tariffs?

Zydus’s Amplitude Acquisition Marks Global Medtech Entry With High Potential In India

Zydus Lifesciences plans to expand global markets for patented products of French orthopedic tech company Amplitude Surgicals which it is acquiring from PE firm PAI Partners and others. Could the European business also serve as a buffer to upheaval in the US amid talks of tariffs?

Is Mittelstand The Missing Piece In India’s Q Quotient?

Can India’s Mittelstand or small and medium enterprises win the quality game and what could help? Sectoral insights from defense and FMCG industries and from other countries like Germany might hold the key for Indian pharma, a panel of experts at a recent event opined.

Genmab Relies On Pipeline As J&J Opts Out Of Next-Gen Darzalex

J&J’s decision about whether to in-license HexaBody-CD38 (GEN3014) was seen as a key milestone for Genmab this year, but without the opt-in the company is discontinuing development.

Bayer Consumer Health Outlook Accelerated By ‘Dynamic’ Cuts To Staff Layers, Efficiency Boost

Key growth driver in consumer health and across Bayer’s sectors, says CEO Bill Anderson, is “dynamic shared ownership program” introduced in January 2024 to "reduce hierarchies, eliminate bureaucracy, streamline structures and accelerate decision-making processes."

Reinventing Prevention: Milken Institute Foresees Another Route Using Private And Public Funding

New funding mechanisms are required to give more momentum to prevention in the community and thereby relieve pressure on overburdened health care providers like the UK National Health Service. So says Simon Radford, a director at global thinktank the Milken Institute, which sees a solution in more funding for community-level prevention.